Dispatch Bio’s virus therapy DV-10 enters phase 1.
ApexOnco Front Page
Recent articles
The company discontinues the Lag3 project in lung cancer.
But the company still has a lot to prove with ERAS-0015.
Three private biotechs enter clinical trials, one targeting KRAS.
But PFS data are lacking, and there are questions about first and second-line plans.
The company will start three phase 3 trials of its G12D project this year.
Early Ibtrozi sales and a low-cost licensing deal with Eisai disappoint investors.
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
